In The News

3 Things to Know After US Supreme Court's Biosimilar Drug Decision

13 Jun 2017

Deanne E. Maynard secured a major victory when the Supreme Court agreed unanimously with Sandoz that the Federal Circuit had erred by delaying introduction of all biosimilars by 180 days. The National Law Journal article “3 Things to Know After US Supreme Court's Biosimilar Drug Decision” provides key takeaways on the decision and what it means for drugmakers moving forward.  

Read the full article.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.